Structured page family:Cost guide

Lanreotide Cost Guide: Insurance, Cash Pay, and Savings

In the United States, Lanreotide costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.

Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Somatuline Depot pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Lanreotide varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.

Price Breakdown

List price (monthly)
~$4,000-$5,000/month
Average wholesale price
~$3,800-$4,800/month
Pharmacy acquisition estimate
~$3,500-$4,500/month
Typical negotiated rate
~$2,800-$3,800/month
Price per dose
~$4,000 per 120 mg injection
Annual cost at list price
~$48,000-$60,000

Pharmacy Price Comparison

PharmacyPrice RangeNotes
Specialty pharmacy$3,800-$5,000/monthRequired

Insurance Coverage Landscape

Commercial plans
~80-90% for approved indications
Medicare Part D
May be Part B (administered in clinic)
Medicaid
Most states cover
VA coverage
On formulary
TRICARE
Covered
Employer plan typical tier
Tier 4-5 specialty; coinsurance 20-40%

Prior Authorization Guide

Required Documentation
  • Acromegaly: GH/IGF-1, MRI
  • NETs: pathology, imaging, receptor status
  • Specialist prescription
Common Denial Reasons
  • No biomarker confirmation
  • Off-label use
  • Not specialist-prescribed
Appeal Template Points
  • FDA-approved
  • Biochemical confirmation
  • Standard of care
  • CLARINET data for NETs
Expected timeline: 3-7 days

Savings Programs and Patient Assistance

Ipsen PAP
manufacturer
Eligibility: Uninsured, ≤400% FPL
Savings: Free
Income limit: ≤400% FPL
Enrollment: moderate
Annual
Copay assistance
copay
Eligibility: Commercially insured
Savings: May reduce significantly
Income limit: None
Enrollment: simple
Cap applies

Generic and Biosimilar Status

No generic currently available
Expected: No generic expected

Cost by Dose

Dose/RegimenMonthlyAnnual
90 mg monthly$4,000$48,000
120 mg monthly$5,000$60,000

Annual Cost Projection

Year 1
$0-$60,000
Year 2
$0-$60,000
Year 3
$0-$60,000
Assumptions
  • Chronic therapy
  • Insurance

Cost-Saving Strategies

  • 1.Apply for Ipsen PAP if uninsured
  • 2.Ensure biomarker documentation for smooth prior auth
  • 3.Compare to octreotide pricing — choose based on efficacy and tolerability, not just cost

International Price Comparison

CountryPrice RangeNotes
UK~£500-700/month (~$630-880)NHS

Need help comparing lanreotide paths?

Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.

Find a lanreotide provider
Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.

Lanreotide Cost FAQ

Sources

  1. 1. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    N Engl J Med • 2014
    Claim type: clinical
    View source →
  2. 2. FDA Information on Lanreotide
    FDA • 2026
    Claim type: regulatory
    View source →

This content is for informational purposes only and does not constitute medical advice.